Xaira Therapeutics Launches with Over $1 Billion to Revolutionize AI-Driven Drug Discovery and Development.
Xaira Therapeutics combines extensive biotech expertise with cutting-edge AI to revolutionize the drug development process, emphasizing both fundamental AI research and practical applications to create transformative medicines.
Company Name: Xaira Therapeutics
Location: San Francisco, CA
Sector: AI Biotechnology
Funding Details: Launched with over $1 billion of committed capital from backers including ARCH Venture Partners, Foresite Capital, F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures, the Parker Institute for Cancer Immunotherapy (PICI), Byers Capital, Rsquared, and SV Angel, among others.
Purpose of Investment: To drive fundamental and translational AI research in biotechnology and transform these advancements into new medicines.
Leadership: Led by CEO Dr. Marc Tessier-Lavigne, former Chief Scientific Officer of Genentech and former President of Rockefeller and Stanford Universities, with key executives from top biotech and tech organizations.
Product: Integrated biotechnology applications involving AI across the drug discovery and development process.
About Company: Xaira Therapeutics combines extensive biotech expertise with cutting-edge AI to revolutionize the drug development process, emphasizing both fundamental AI research and practical applications to create transformative medicines.
